|
S1068
|
Crizotinib (PF-02341066) |
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley. |
|
|
|
S1111
|
Foretinib (GSK1363089, XL880) |
XL880 (GSK1363089, EXEL-2880) is an ATP-competitive inhibitor of MET and KDR with IC50 of 0.4 nM and 0.9 nM, respectively. |
|
|
|
S1070
|
PHA-665752 |
PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM. |
|
|
|
S1080
|
SU11274 |
SU11274 is a selective Met inhibitor with IC50 of 10 nM. |
|
|
|
S1094
|
PF-04217903 |
PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM. |
|
|
|
S7067
|
EMD 1214063 |
EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 6 nM. |
|
|
|
S1119
|
XL-184 free base (Cabozantinib) |
XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
|
|
|
S1112
|
SGX-523 |
SGX-523 is a selective Met inhibitor with IC50 of 4 nM. |
|
|
|
S1561
|
BMS 777607 |
BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. |
|
|
|
S2753
|
ARQ 197 (Tivantinib) |
ARQ-197 is a novel and selective human c-Met inhibitor with IC50 of 0.1 μM. |
|
|